<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830764</url>
  </required_header>
  <id_info>
    <org_study_id>LTS-ACN06</org_study_id>
    <nct_id>NCT01830764</nct_id>
  </id_info>
  <brief_title>Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers</brief_title>
  <official_title>An Open-label Safety and Tolerability Study of LTS 0.3% With Red Light Applied to the Backs of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is assess the safety and tolerability of lemuteporfin topical&#xD;
      solution (LTS) with exposure to red light (PDT), when applied to the backs of healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, safety study in healthy volunteers. Two cohorts, of 6 subjects each,&#xD;
      will be enrolled (total subjects = 12). Each subject will have test areas identified on the&#xD;
      back and receive a single LTS, vehicle solution and red light (PDT) applied to the test areas&#xD;
      on the back. Subjects will be followed for safety at study visits occurring on Day 1&#xD;
      (baseline and treatment), Day 2, and Day 7.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>Adverse events and local tolerability assessed at pre and immediately post treatment, at Day 1 and Day 7 following treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Red light dose (PDT) 75 J/cm2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red Light (PDT) 150 J/cm2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Red Light (PDT)</intervention_name>
    <description>LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)</description>
    <arm_group_label>Red Light (PDT) 150 J/cm2</arm_group_label>
    <arm_group_label>Red light dose (PDT) 75 J/cm2</arm_group_label>
    <other_name>LTS-PDT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults 18 years of age or older&#xD;
&#xD;
          2. Fitzpatrick skin types I-IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current pregnancy or lactation.&#xD;
&#xD;
          2. Presence of severe facial acne, acne fulminans or conglobata, or nodulocystic acne.&#xD;
&#xD;
          3. Poor skin condition on the back, including erythema, dryness, sunburn, dermatological&#xD;
             malignancies, infections, cuts, abrasions, tattoo, excess of hair or any other skin&#xD;
             condition&#xD;
&#xD;
          4. Subjects who have used any agents known to produce significant photosensitivity&#xD;
             reactions (tetracyclines, phenothiazines, trimethoprim, etc.) within 2 weeks of Day 1&#xD;
             or 5 half-lives, whichever is longer.&#xD;
&#xD;
          5. Subjects who have used any medicated topical therapy on the back within 3 days of Day&#xD;
             1.&#xD;
&#xD;
          6. Chronic treatment with low dose aspirin, a non-steroidal anti inflammatory drug&#xD;
             (NSAID), or an anticoagulant regimen such as warfarin (Coumadin).&#xD;
&#xD;
          7. Abnormal findings on screening ECG deemed clinically significant by the Investigator.&#xD;
&#xD;
          8. Active participation in an experimental therapy study or experimental therapy within&#xD;
             30 days of Day 1.&#xD;
&#xD;
          9. Screening clinical chemistry or hematology laboratory value that is considered&#xD;
             clinically significant, in the opinion of the Investigator.&#xD;
&#xD;
         10. Subjects who are a poor medical risk because of other systemic diseases or active&#xD;
             uncontrolled infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S Dosik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TKL Research Inc (Research Clinics Division)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TKL Research Inc (Research Clinics Division)</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 10, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

